Bioventus Inc. (BVS) Stock Price & Analysis
Bioventus Inc. (BVS) closed at USD 14.65 on Wednesday, October 28, 2026, up 1.59% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 14.42; the Oct 28, 2026 session ranged USD 14.26–14.75 on volume of 590,107 shares. Market capitalization is $1.00B, with a 52-week range of USD 6.47–15.89 (NMS). Source: Nexqual, retrieved October 29, 2026 at 00:32 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BVS.md
Key facts (BVS)
- Last four reported quarters (through Jun 27, 2026): revenue $582M, net income $54.5M (9.4% margin), free cash flow $94.3M (SEC filings).
- Valuation: P/E 18.4x (avg 22.6x at the last 1 fiscal year-ends), EV/EBITDA 14.6x, net debt $219M.
- Earnings quality: non-operating income -$19.6M vs operating income $58.3M over the last four quarters; P/E excluding non-operating income ≈13.5x (estimate: non-operating income taxed at the company's 0% effective rate).
- Analysts: Buy (mean 1.60 on a 1–5 scale) (5 analysts), mean target USD 17.6 (range 15–19).
- Total return with dividends: 1Y +113.0% vs S&P 500 +13.2%; 5Y -3.0% vs S&P 500 +79.8%.
- Next earnings: 2026-11-02, EPS estimate USD 0.16, revenue estimate $150M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BVS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $431M | $512M | $512M | $573M | $568M | $582M |
| Gross profit | $303M | $331M | $328M | $388M | $388M | — |
| Operating income | $12.1M | -$167M | -$81.7M | -$15.2M | $54.0M | $58.3M |
| Net income | $19.4M | -$159M | -$156M | -$36.1M | $22.7M | $54.5M |
| EPS (diluted) | -$0.15 | -$2.59 | -$2.49 | -$0.56 | $0.33 | — |
| Free cash flow | $9.5M | -$15.0M | $8.0M | $37.8M | $72.1M | $94.3M |
| Gross margin | 70.3% | 64.6% | 64.1% | 67.7% | 68.3% | — |
| Operating margin | 2.8% | -32.7% | -16.0% | -2.7% | 9.5% | 10.0% |
| Net margin | 4.5% | -31.0% | -30.5% | -6.3% | 4.0% | 9.4% |
| Revenue growth | +34.2% | +18.8% | +0.0% | +11.9% | -0.9% | — |
| Cash + short-term investments | $43.9M | $30.2M | $37.0M | $41.6M | $51.2M | — |
| Total debt | $358M | $418M | $395M | $336M | $294M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 27, 2026) (BVS)
P/E 18.4x · P/E ex non-operating (est.) ≈13.5x · P/S 1.7x · EV/EBITDA 14.6x · EV/Sales 2.1x · P/FCF 10.6x · P/B 4.4x · FCF yield 9.42% · Earnings yield 5.44% · Net debt $219M · EV $1.22B
P/E at fiscal year-ends: Dec 2025 22.6x.
Analysts (BVS)
Consensus Buy (mean 1.60 on a 1–5 scale), 5 analysts; mean target USD 17.6 (low 15, high 19).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-17 | Canaccord Genuity | Target raised | Buy | $15 → $19 |
| 2026-08-17 | Cantor Fitzgerald | Reiterated | Overweight | $15 |
Total return (dividends reinvested) (BVS)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +113.0% | -3.0% |
| S&P 500 (SPY) | +13.2% | +79.8% |
| Per year | +114.0% | -0.6% |
| Volatility (annualized) | 50.6% | 82.5% |
| Max drawdown | -27.5% (May 2026→Jun 2026) | -94.0% (Nov 2021→Apr 2023) |
BVS earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 5, 2026 | Quarter ended Jun 30, 2026 | $0.22 | $0.22 | In line | +4.2% |
| May 6, 2026 | Quarter ended Mar 31, 2026 | $0.15 | $0.07 | Beat +114.3% | -0.3% |
| Mar 5, 2026 | Quarter ended Dec 31, 2025 | $0.24 | $0.22 | Beat +9.1% | -0.7% |
| Nov 4, 2025 | Quarter ended Sep 30, 2025 | $0.15 | $0.12 | Beat +25.0% | +12.5% |
| Aug 6, 2025 | — | — | — | — | +12.9% |
| May 6, 2025 | — | — | — | — | -6.3% |
| Mar 11, 2025 | — | — | — | — | +15.0% |
| Nov 5, 2024 | — | — | — | — | -17.7% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
BVS recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 27, 2026 | Schedule 13G/A | BlackRock, Inc.: 4.9% of shares, passive 5%+ holder (amended) |
| Aug 5, 2026 | 10-Q | Quarterly report · period ended Jun 27, 2026 |
| Aug 5, 2026 | 8-K | Quarterly results; Other material event “As previously announced, following receipt of a recent unsolicited acquisition proposal from a party interested in acquiring the Company and multiple other expressions of interest, the Company's Board of Directors (the "Board") established a committee of independent directors, which, with the assistance of independent advisors, is evaluating a range of strategic alternatives, including but not limited to a sale of the Company or continued execution of the Company's standalone plan, aimed at maximizing value for…” |
| Jul 27, 2026 | Schedule 13G | BlackRock, Inc.: 5.0% of shares, passive 5%+ holder |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
BVS revenue by business segment (quarter ended Jun 27, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| U.S. | $134.5M | 87.8% | +4.4% |
| International | $18.7M | 12.2% | -0.8% |
| Total revenue | $153.2M | 100% | — |
BVS revenue by region (quarter ended Jun 27, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| U.S. | $134.5M | 87.8% | +4.4% |
| International | $18.7M | 12.2% | -0.8% |
| Total revenue | $153.2M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
BVS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | BV | “•our principal asset is our interest in BV LLC, and, accordingly, we depend on distributions from BV LLC to pay our taxes and expenses, including payments under the Tax Receivable Agreement.” |
| Competitor | Johnson & Johnson (JNJ) | “Our Pain Treatments that we own or distribute compete with products from Ferring Pharmaceutical Inc., Fidia Farmaceutici S.p.A., Johnson & Johnson, Zimmer Biomet Holdings, Inc., Arthrex, Inc., Emcyte Corporation and Channel-Markers Medical, and for peripheral nerve stimulation specifically, we compete with SPR Therapeutics, Nalu and Curonix.” |
Quoted from the company's 10-K filed Mar 5, 2026.
BVS company outlook (results filed Aug 5, 2026)
- “Bioventus is reaffirming its 2026 Financial Guidance provided on May 6, 2026.”
- “For the twelve months ending December 31, 2026, the Company expects: • Net sales of $600 million to $610 million.”
Quoted word-for-word from the SEC 8-K results press release.
BVS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.16 | $0.18 | -9.1% | $149.5M | 5 |
| Next quarter (ends Dec 2026) | $0.25 | $0.24 | +4.2% | $170.0M | 5 |
| Current fiscal year (ends Dec 2026) | $0.78 | $0.78 | -0.3% | $604.8M | 5 |
| Next fiscal year (ends Dec 2027) | $0.92 | $0.91 | +1.3% | $645.6M | 5 |
BVS options: expected move
Options price a move of about ±15.5% (±$2.25) by Nov 20, 2026, which includes earnings on Nov 2, 2026. Over the last 8 reports the stock moved ±8.7% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 23 | 75.1% | ±15.5% |
| Jan 15, 2027 | 79 | 66.0% | ±24.9% |
| Apr 16, 2027 | 170 | 68.7% | ±37.3% |
30-day implied volatility 74.8% vs 39.7% realized over the last 30 trading days. Put/call ratio (volume) 0.13. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 00:32 UTC)
| Price | USD 14.65 |
|---|---|
| Change | ▲ 1.59% (up) |
| Previous Close | USD 14.42 |
| Open | USD 14.32 |
| Day Range | USD 14.26 – 14.75 |
| 52-Week Range | USD 6.47 – 15.89 |
| Volume | 590,107 shares |
| Market Cap | $1.00B |
| Exchange | NMS |
Technical Analysis (BVS)
Nexqual's technical model rates BVS "STRONG BUY" based on 5 bullish and 0 bearish signals across 126 daily candles, as of October 29, 2026 at 00:32 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.14 (neutral) |
| vs SMA50 | Above (USD 13.71) |
| MACD | 0.31 (positive) |
Analyst Ratings (BVS)
Wall Street analysts rate BVS "Buy" based on 5 analysts, with a mean price target of USD 17.6 (range USD 15–19), per Nexqual as of October 29, 2026 at 00:32 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 17.6 |
| High Target | USD 19 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (BVS)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD 0.16 |
| Revenue Estimate | $149.52M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.22 vs est 0.22 ▲ beat |
| 2026-03-31 | USD 0.15 vs est 0.07 ▲ beat |
| 2025-12-31 | USD 0.24 vs est 0.22 ▲ beat |
| 2025-09-30 | USD 0.15 vs est 0.12 ▲ beat |
Source: Nexqual, October 29, 2026 at 00:32 UTC.
Financials & Fundamentals (BVS)
| Total Revenue | $581.85M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +3.80% |
| Gross Margin | +68.65% |
| Operating Margin | +12.23% |
| Profit Margin | +9.36% |
| ROE | +25.68% |
| Debt / Equity | 0.95 |
| Current Ratio | 1.69 |
| Total Cash | $30.39M |
| Total Debt | $263.75M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $94.29M (16.2% of revenue) |
Source: Nexqual, October 29, 2026 at 00:32 UTC.
Financial Health Score (BVS)
Nexqual rates Bioventus Inc.'s overall financial health "Solid" across five dimensions, as of October 29, 2026 at 00:32 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 69%, operating 10% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Mixed — $29M cash and investments vs $248M debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $94M (last 4 quarters to Jun 2026, SEC), 16% margin |
| Efficiency | Strong — ROE 24%, ROA 8.1% (last 4 quarters, SEC) |
Ownership (BVS)
| Insider Ownership | +11.65% |
|---|---|
| Institutional Ownership | +84.65% |
| Shares Outstanding | 68.31M |
| Float | 34.30M |
| Short % of Float | +6.78% |
Source: Nexqual, October 29, 2026 at 00:32 UTC.
Leadership (BVS)
Bioventus Inc. is led by Robert E. Claypoole, President, CEO & Director, per Nexqual as of October 29, 2026 at 00:32 UTC.
| President, CEO & Director | Robert E. Claypoole |
|---|---|
| Senior VP & CFO | Mark L. Singleton |
| Senior Vice President of Operations | Mike Crowe B.S. |
| Vice President of Investor Relations & Treasurer | David Crawford |
Major Backers & Investors (BVS)
Notable institutional backers of Bioventus Inc. include Essex Woodlands Management Inc., Juniper Investment Company, LLC, Nantahala Capital Management, LLC, according to Nexqual as of October 29, 2026 at 00:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Essex Woodlands Management Inc. | 19.06% |
| Juniper Investment Company, LLC | 10.16% |
| Nantahala Capital Management, LLC | 8.78% |
| Royce & Associates LP | 2.68% |
| American Century Companies Inc | 1.98% |
| Brown Advisory Funds-Brown Advisory Small-Cap Fundamental Value Fund | 1.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.03% |
| Vanguard Group | 2.56% |
| Geode Capital | 2% |
| Dimensional Fund Advisors | 1.65% |
Source: Nexqual, October 29, 2026 at 00:32 UTC.
From Bioventus Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- The neXus Ultrasonic Surgical System ("neXus") is a leading ultrasonic surgical platform that combines all the features of our Surgical Solutions applications, including BoneScalpel, BoneScalpel Access, SonaStar Elite, SonicOne and SonaStar into a single fully integrated system, setting a foundation for future developments to fulfill unmet customer needs.
- We also own 19 issued U.S. patents, 26 issued foreign patents, and two pending foreign patent applications directed to our SonicOne System, including foreign patents and patent applications in Asia, Canada, and Europe.
- We seek to protect our proprietary technology and manufacturing process, in part, by confidentiality and invention assignment agreements with employees, consultants, scientific advisors and contractors, under which they are bound to assign to us certain inventions that are made during the course of performing work for us and relate to our business.
- The FDA may withdraw marketing authorizations for drugs, biologics (including Section 361 HCT/Ps) and/or medical devices if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.
Partnerships
- In 2025, we entered into an agreement with Apex Biologix to be the exclusive distributor of their XCELL PRP System in the United States, specifically for orthopedic and sports medicine markets.
Legal & Regulatory Risks (Item 1A, quoted)
- Our products and operations are subject to extensive governmental regulation, and our failure to comply with applicable requirements could cause our business to suffer.
- Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and harm our reputation, business, results of operations and financial condition.
- We may be subject to enforcement action if we engage in improper claims submission practices and resulting audits or denials of our claims by government agencies could reduce our net sales or profits and could lead to significant civil or criminal penalties and other liability.
- The FDA regulatory process is expensive, time-consuming and uncertain, and the failure to obtain and maintain required regulatory clearances and approvals could prevent us from commercializing our products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INSP | Inspire Medical Systems, Inc. | USD 70.97 | ▼ 0.46% |
| ESTA | Establishment Labs Holdings Inc | USD 68.97 | ▲ 3.02% |
| BFLY | Butterfly Network, Inc. | USD 7.81 | ▲ 5.83% |
| UFPT | UFP Technologies, Inc. | USD 286 | ▼ 3% |
| TMDX | TransMedics Group, Inc. | USD 66.9 | ▼ 4.06% |
| ALMR | Alamar Biosciences, Inc. | USD 34.3 | ▲ 7.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 00:32 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt